← Eichor
Study identifier: NCT07303296 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients

Condition: Leber Hereditary Optic Disease  ·  Sponsor: GenSight Biologics

PhasePhase 2
Planned participants14
Who can joinAll sexes, 15 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this Clinical trial is to assess the safety and efficacy of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy (LHON)

This description comes directly from the study's public registry record.

Talk to the study team

GenSight Biologics  ·  clinics@gensight-biologics.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hopital national des quinze-vingtsParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07303296